3. Rahier, J.F., et al., Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048-55.
4. Cullen, G., et al., Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11-12):1318-27.
5. Shmidt, E., et al., Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012.67(5): 179-85.
6. Guerra, I., et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894-901.
7. Klufas, D.M., J.M. Wald, and B.E. Strober. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Pediatr Dermatol. 2016;33(2):142-9.
8. Rinawi, F., et al., Ustekinumab for resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62(4):34-5.
9. Bishop, C., et al. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2016;63(3):348-51.
10. Min MS, Shroff A, Rose S, Lebwohl M, Guttman-Yassky E. Ustekinumab as therapy for psoriasis in a 2-year-old girl. J Eur Acad Dermatol Venereol. 2016;30(11):109-110.
11. Bertrand V, El Haite A, Carré D. Efficiency of ustekinumab in Crohn's disease with severe psoriasiform rash induced by biotherapies in an adolescent. Pediatr Dermatol. 2017;34(4): 214-215
12. Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximabinduced psoriasis and arthritis associated with Crohn's disease. Biologics. 2018;19(12):69-73.
4. Cullen, G., et al., Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11-12):1318-27.
5. Shmidt, E., et al., Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012.67(5): 179-85.
6. Guerra, I., et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894-901.
7. Klufas, D.M., J.M. Wald, and B.E. Strober. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Pediatr Dermatol. 2016;33(2):142-9.
8. Rinawi, F., et al., Ustekinumab for resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62(4):34-5.
9. Bishop, C., et al. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2016;63(3):348-51.
10. Min MS, Shroff A, Rose S, Lebwohl M, Guttman-Yassky E. Ustekinumab as therapy for psoriasis in a 2-year-old girl. J Eur Acad Dermatol Venereol. 2016;30(11):109-110.
11. Bertrand V, El Haite A, Carré D. Efficiency of ustekinumab in Crohn's disease with severe psoriasiform rash induced by biotherapies in an adolescent. Pediatr Dermatol. 2017;34(4): 214-215
12. Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximabinduced psoriasis and arthritis associated with Crohn's disease. Biologics. 2018;19(12):69-73.
AUTHOR CORRESPONDENCE
Michael I. Gordon DO gordonmi99@gmail.com
